Results 101 to 110 of about 38,942 (318)

Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab [PDF]

, 2011
PURPOSE: To evaluate the long-term safety and efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (CNV). METHODS: Three-year retrospective, nonrandomized, interventional case series.
Cachulo, ML, Figueira, J, Fonseca, P, Franqueira, N, Marques, I, Pires, I, Silva, R   +6 more
core   +1 more source

Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study

PLoS ONE, 2020
Purpose To assess the one-year effectiveness and safety of ranibizumab 0.5 mg in treatment- naïve patients with diabetic macular edema (DME) enrolled in the real-world LUMINOUS study. Patients and methods A 5-year, prospective, observational, open-label,
P. Mitchell, T. Sheidow, M. Farah, S. Mahmood, A. Minnella, N. Eter, B. Eldem, H. Al-Dhibi, W. Macfadden, S. Parikh, C. Dunger-Baldauf, M. Mahgoub, U. Schmidt-Erfurth   +12 more
semanticscholar   +1 more source

Clinical characteristics and treatment outcomes of bilateral myopic macular neovascularization in high myopic patients

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the clinical features and treatment outcomes of bilateral myopic macular neovascularization (mMNV). Methods This single‐centre retrospective study included patients with bilateral high myopia who were newly diagnosed with unilateral mMNV (first eye) between January 2008 and July 2020.
Soo Hyun Lim, Kunho Bae, Chang Ki Yoon, Eun Kyoung Lee, Kyu Hyung Park, Un Chul Park   +5 more
wiley   +1 more source

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

JAMA ophthalmology, 2019
This randomized clinical trial compares the clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for the management of macular edema secondary to central retinal vein occlusion.
P. Hykin, A. T. Prevost, Joana C Vasconcelos, C. Murphy, J. Kelly, J. Ramu, B. Hounsome, Yit C. Yang, S. Harding, A. Lotery, U. Chakravarthy, S. Sivaprasad   +11 more
semanticscholar   +1 more source

Interventions for submacular haemorrhage: A systematic review and network meta‐analysis of controversies—On behalf of the Spanish Vitreo‐Retinal Society (SERV)

Acta Ophthalmologica, EarlyView.
Abstract Purpose This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice. Method A systematic review was conducted following the PRISMA guidelines.
Salvador Pastor‐Idoate, Pablo Redruello‐Guerrero, Laura de Juan Hernández, Gregorio Benites‐Narcizo, Mario Rivera‐Izquierdo, José García‐Arumí, José Carlos Pastor Jimeno   +6 more
wiley   +1 more source

SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the role of spectral domain optical coherence tomography (SD‐OCT)‐based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti‐vascular endothelial growth factor (VEGF) therapy.
Ken K. Tsang, Vivian W. K. Hui, Christopher M. K. Pang, Ziqi Tang, Dawei Yang, Truong X. Nguyen, Shaheeda Mohamed, Timothy Y. Y. Lai, Carol Y. Cheung, Simon K. H. Szeto   +9 more
wiley   +1 more source

Prognostic Factors of Early Morphological Response to Treatment with Ranibizumab in Patients with Wet Age-Related Macular Degeneration [PDF]

, 2015
Aim. To assess the significance of age, gender, baseline best corrected visual acuity, baseline macula thickness, and type and size of choroidal neovascularization in early morphological therapeutic response to ranibizumab treatment in patients with the ...
Chrapek Oldřich, Dušek Ladislav, Jarkovský Jiří, Jirková Barbora, Kolář Petr, Pitrová Šárka, Studnička Jan, Řehák Jiří, Šín Martin   +8 more
core   +4 more sources

Ranibizumab for the treatment of degenerative ocular conditions

Clinical Ophthalmology, 2014
Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these ...
Triantafylla, Magdalini, Massa, Horace, Dardabounis, Doukas, Gatzioufas, Zisis, Kozobolis, Vassilios, Ioannakis, Konstantinos, Perente, Irfan, Panos, Georgios   +7 more
openaire   +7 more sources

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source